1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Selecta chooses Takashi Kei Kishimoto for CSO

 
• By Gemma Sharman

Selecta Biosciences, a biopharmaceutical company developing novel targeted vaccines and immunotherapies, has appointed Dr Takashi Kei Kishimoto chief scientific officer reporting to Dr Werner Cautreels, Selecta's CEO. Dr Kishimoto most recently served as vice-president of research at Momenta Pharmaceuticals, where he led a team advancing novel and complex generic products for inflammation, oncology and cardiovascular disease.

Selecta Biosciences, a biopharmaceutical company developing novel targeted vaccines and immunotherapies, has appointed Dr Takashi Kei Kishimoto chief scientific officer reporting to Dr Werner Cautreels, Selecta's CEO. Dr Kishimoto most recently served as vice-president of research at Momenta Pharmaceuticals, where he led a team advancing novel and complex generic products for inflammation, oncology and cardiovascular disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

More from Therapeutic Category

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging

 
• By Aakash Babu

The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.